Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't

Morris Shannon, Chief Medical Officer of Erasca (ERAS 5.07%), reported the exercise and immediate sale of 20,000 shares of Common Stock for a transaction value of approximately $301,000, according to a SEC Form 4 filing.

Transaction summary

Transaction value based on SEC Form 4 weighted average purchase price ($15.04); post-transaction direct holdings were zero following the transaction.

Key questions

• What was the structure and context of this transaction?
  The transaction involved exercising 20,000 options for Common Stock, immediately followed by a sale of the same number of shares.
• How did this filing affect Morris Shannon’s direct and beneficial ownership?
  Direct Common Stock holdings were reduced to zero as a result of this sale, but Shannon continues to hold rights to acquire up to 515,800 shares through stock options, which are not included in direct share ownership until exercised.
• What was the impact on overall insider exposure?
  While the direct equity position in Common Stock was reset to zero, total beneficial ownership remains high due to substantial outstanding options, maintaining alignment with potential future equity upside.
• How does the transaction compare to prior activity and available capacity?
  This is the first open-market sale by Shannon; the full liquidation of direct Common Stock reflects the exhaustion of available shares rather than a discretionary reduction, and remaining equity exposure is now entirely options-based.

Company overview

• 1-year price change calculated using March 26, 2026 as the reference date.

Company snapshot

• Erasca’s products include clinical-stage oncology drug candidates targeting the RAS/MAPK pathway, such as ERAS-007 (ERK1/2 inhibitor), ERAS-601 (SHP2 inhibitor), and ERAS-801 (CNS-penetrant EGFR inhibitor).
• The company operates a research-driven model focused on developing and commercializing targeted therapies for cancer, with future revenues expected from drug approvals and licensing agreements.
• Its Primary customers are anticipated to be healthcare providers, oncology specialists, and hospital systems treating patients with RAS/MAPK pathway-driven cancers.

Erasca is a clinical-stage biotechnology company specializing in the development of precision oncology therapeutics for RAS/MAPK pathway-driven cancers. The company leverages a robust pipeline of targeted drug candidates and deep expertise in molecular oncology to address significant unmet medical needs. With a focused strategy on innovative cancer therapies, Erasca aims to establish a competitive edge in the rapidly evolving oncology market.

What this transaction means for investors

Shannon’s direct share count hit zero after this sale — but that’s less alarming than it looks. Every share came from a single option exercise under a 10b5-1 trading plan she put in place in June 2024, and the zero balance simply reflects that those were the only direct shares she held. Her 515,800 remaining options keep her exposure to Erasca’s future squarely intact.

Morris has been at Erasca since 2022 and brings over 20 years of oncology drug development experience across GSK, AstraZeneca, and G1 Therapeutics. A sector veteran cashing out a small tranche of vested options under a preplanned program isn’t a signal — it’s routine compensation management.